Sino Biopharmaceutical Limited
1177
Classifica tra le azioni
#1753
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Prezzo delle azioni
$0.69080164
Capitalizzazione di mercato
$12.30B
Variazione (1 giorno)
2.86%
Variazione (1 anno)
-96.45%
Paese
HK
Scambia Sino Biopharmaceutical Limited (1177)
Categoria
Healthcare
Storico dividendi per Sino Biopharmaceutical Limited (1177)
Sino Biopharmaceutical Limited (simbolo azionario: 1177) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Sino Biopharmaceutical Limited (1177) dal 2026 al 2026
Pagamenti annuali dei dividendi
| Anno | Dividendo (rettificato per split azionari) | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
Elenco di tutti i pagamenti di dividendi
| Anno | Dividendo | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
Dividendi di aziende simili o concorrenti
| Azienda | Numero di pagamenti di dividendi | Il paese |
|---|---|---|
| 23.00% |
US
|
|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
